^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anal Carcinoma

    No biomarker
    Anal Carcinoma
    MIXE
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    TPF
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    nivolumab
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    FOLFOX
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    carboplatin + paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    FOLFCIS
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    cisplatin + 5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    mFOLFOX6
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    DCF
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    cisplatin + docetaxel
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    cisplatin + carboplatin
    Sensitive
    :
    A2
    No biomarker
    Anal Carcinoma
    cisplatin + 5-fluorouracil + capecitabine
    Sensitive
    :
    A2
    PD-L1 expression
    Anal Carcinoma
    pembrolizumab
    Sensitive
    :
    C1
    PD-L1 overexpression + TMB-H
    Anal Carcinoma
    EGFR inhibitor + Immunotherapy
    Sensitive
    :
    C3
    CD163 expression
    Anal Carcinoma
    toripalimab
    Sensitive
    :
    C3
    CD4 expression
    Anal Carcinoma
    toripalimab
    Sensitive
    :
    C3
    PD-L1 expression
    Anal Carcinoma
    toripalimab
    Sensitive
    :
    C3
    PD-L1 amplification + PD-L2 amplification + TMB-H
    Anal Carcinoma
    pembrolizumab
    Sensitive
    :
    C4